Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Takács Ferenc
Kotmayer Lili
Czeti Ágnes
Szalóki Gábor
László Tamás
Mikala Gábor
Márk Ágnes
Masszi András
Farkas Péter
Plander Márk
Weisinger Júlia
Demeter Judit
Fekete Sándor
Szerafin László
Deák Beáta Margit
Szaleczky Erika
Sulák Adrienn
Borbényi Zita
Barna Gábor
Dokumentumtípus: Cikk
Megjelent: 2022
Sorozat:PATHOLOGY AND ONCOLOGY RESEARCH 28
Tárgyszavak:
Klinikai orvostan
doi:10.3389/pore.2022.1610659

mtmt:33104808
Online Access:http://publicatio.bibl.u-szeged.hu/25676
Leíró adatok
Tartalmi kivonat:Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to find phenotypic markers on CLL cells the expression of which may correlate with the appearance of ibrutinib resistance.
Terjedelem/Fizikai jellemzők:7
ISSN:1219-4956

Hasonló tételek